First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected...
First regulatory approval for iza-bren (BL-B01D1), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) Represents an important n...
Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval ...
As the biopharmaceutical industry enters a new phase of growth, manufacturers are under increasing pressure to deliver greater capacity, accelerate...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, arrives at a time when genomic medicine is rapidly reshaping the future of heal...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, comes at a pivotal moment for emerging biotech companies. While scienti...
As biotech innovators pursue increasingly complex therapies, the path from discovery to clinical proof of concept is becoming more challenging than ever. F...
NDA submission supported by positive Phase 3 data recently published in JAMA Neurology. Ecopipam is a first-in-class selective dopamine D1 receptor an...
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for...
Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of dis...
IDBS, a Danaher company and leading provider of cloud software for biopharma, and Alchemi, a leading applied AI company serving the world's largest pharm...
Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) progra...
ZoBio, a boutique problem-solving Contract Research Organization (CRO) specializing in early gene-to-lead discovery, today announced the launch of its co...
Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes Accelerat...
© 2026 Biopharma Boardroom. All Rights Reserved.
